Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.48 |
| ▸ | TCF4 | P15884 | 2/20 | 0.47 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.47 |
| ▸ | PLAT | P00750 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 7/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18138850 | 0.92 | PFKFB3 (0.57) | HCRTR2HCRTR1PFKFB3 | |
| SCHEMBL18138786 | 0.89 | HCRTR2 (0.54) | HCRTR2HCRTR1 | |
| SCHEMBL18138808 | 0.88 | HCRTR2 (0.52) | HCRTR2HCRTR1 | |
| SCHEMBL18138783 | 0.88 | HCRTR2 (0.64) | HCRTR2HCRTR1 | |
| SCHEMBL2875983 | 0.87 | ADRB2 (0.53) | PLAUHCRTR2 | |
| SCHEMBL18138818 | 0.85 | HCRTR2 (0.55) | HCRTR2HCRTR1 | |
| SCHEMBL18138812 | 0.83 | HCRTR2 (0.52) | HCRTR2HCRTR1 | |
| SCHEMBL18300923 | 0.83 | PLAU (0.43) | PLAUHCRTR2TCF4CTNNB1PLAT | |
| SCHEMBL18138804 | 0.81 | HCRTR2 (0.53) | HCRTR2HCRTR1 | |
| SCHEMBL18138799 | 0.80 | HCRTR2 (0.64) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3081553-B1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIV TSUKUBA (JP) | 2018-12-12 | — | — | EP | disclosed |
| US-9815787-B2 | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof | UNIVERSITY OF TSUKUBA (JP) | 2017-11-14 | — | — | US | disclosed |
| US-20160362376-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | UNIVERSITY OF TSUKUBA (JP) | 2016-12-15 | — | — | US | disclosed |
| EP-3081553-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | University of Tsukuba (JP) | 2016-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362376-A1 | SULFONAMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF | HCRTR2, HCRTR1, NPSR1 | PLAU 2613/4885HCRTR2 1/4885TCF4 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.